resDetect™ Human FGF2 ELISA Kit (Residue Testing)
产品概述（Product Overview）
resDetect™ Human FGF2 ELISA Kit (Residue Testing) is based on the ELISA sandwich method and is used to detect and quantitatively determine GMP human FGF2 residues in cell culture supernatants, serum, and plasma. The kit contains GMP human FGF2 (ACROBiosystems, cat# GMP-FGCH17) to ensure accurate assay results and is designed to provide a reliable solution for CAR-T product quality assessment during drug development and CMC quality control stages. It can also be used as a universal detection tool for the quantitative determination of human FGF2
重构方法（Reconstitution）
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
存储（Storage）
背景（Background）：FGF2
FGF basic (also known as FGF2 and HBGF-2) is an 18-34 kDa, heparin-binding member of the FGF superfamily of molecules. Superfamily members are characterized by the presence of a centrally placed beta -trefoil structure. FGF acidic (FGF-1) and FGF basic (FGF2) were the first two identified FGFs, and the designations acidic and basic refer to their relative isoelectric points. Human FGF basic is 288 amino acids (aa) in length. There are multiple start sites, four of which utilize atypical CUG codons, and one that initiates at an AUG start site. The four CUG start sites generate high molecular weight (HMW) FGF basic. There is a 34 kDa, 288 aa form, a 24 kDa, 210 aa form, a 22.5 kDa, 201 aa form, and a 22 kDa, 196 aa form. All are retained intracellularly, undergo extensive methylation, and possess one or more nuclear localization signals (NLS). The AUG initiating form is 18 kDa and 155 aa in length. There is no signal sequence (ss). It is, however, secreted directly through the plasma membrane via a mechanism that appears to be dependent upon tertiary structure. In place of a ss, there is purportedly a 9 aa N-terminal prosegment that precedes a 146 aa mature segment. Early isolations of 18 kDa bovine FGF basic yielded 146 aa molecules, an effect attributed to the presence of acid proteases. The molecule contains a heparin-binding site (aa residues 128-144), and undergoes phosphorylation at Ser117. There is also an ill-defined C-terminal NLS that may be more “functional” (or 3-dimensional) than structural. Human 146 aa FGF basic is 97% aa identical to mouse FGF basic.
关键字： FGF2;FGF2试剂盒;FGF2 ELISA试剂盒;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。